Pharmaceuticals
NMPA Clears IND for First T-Cell Receptor (TCR) T Cell Therapy to Treat Hepatitis B virus (HBV) associated hepatocellular carcinoma (HCC)
SINGAPORE, March 11, 2022 /PRNewswire/ -- Singapore-based SCG Cell Therapy Pte Ltd ("SCG"), a leading biotechnology company, today announced that the China National Medical Products Administration (NMPA) has cleared its Investigational New Drug (IND) application for SCG101, the company's first T-...
2022-03-11 21:07
5604
Gan & Lee Pharmaceuticals Begins First-In-Human Trial in U.S. for Investigational Drug, GZR18
BEIJING and BRIDGEWATER, N.J., March 11, 2022 /PRNewswire/ -- Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), is pleased to announce the first subject has been dosed in our Phase I, double-blinded, randomized, placebo-controlled, sequential, sing...
2022-03-11 03:35
4751
Novavax Announces Launch of Global Vaccine Education Programs
- 'We Do Vaccines' and 'Know Our Vax' are new educational efforts that provide information regarding vaccines - Programs explain Novavax' commitment to vaccine development and innovation GAITHERSBURG, Md., March 10, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company de...
2022-03-10 22:00
5214
Everest Medicines Announces that Licensing Partner Venatorx Pharmaceuticals Reports Positive Results from Pivotal Phase 3 Cefepime-Taniborbactam Trial
SHANGHAI, March 10, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Venatorx Pharmaceuticals, reported positive results from its pivotal Phase 3 study, CERTAIN-1 (Cefepime Rescue with Taniborbactam in cUTI), evaluating cefepime-taniborbactam, an in...
2022-03-10 19:05
4603
Transcenta Presented Safety / Tolerability and Preliminary Anti-tumor Activity Data in Gastric and Pancreatic Cancers of TST001 Monotherapy from China Phase I Clinical Trial at the 2022 International Gastric Cancer Congress
SUZHOU, China, March 10, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that Transcenta has ...
2022-03-10 08:30
4360
Insilico Medicine enters research collaboration with the University of Zurich to apply Insilico's generative Artificial Intelligence platform for the discovery of potential therapeutics for Cystinosis
- Cystinosis is a rare genetic disease affecting 1 in 100,000-200,000 live births and poses a lifelong risk to those affected. Cystinosis slowly destroys the body's organs including the kidneys, eyes, thyroid, muscles, liver, pancreas, gonads, and brain. - There are currently no curative treatme...
2022-03-10 00:57
3184
Kusum Healthcare recognized as one of Best Places to Work in Philippines for 2022
MANILA, Philippines, March 9, 2022 /PRNewswire/ -- Kusum Healthcare, a leading tech-driven pharmaceutical group, has been recently awarded the Best Place to Work certification inPhilippines for 2022. During the company assessment, 97% of employees recommended the organization illustrating the com...
2022-03-09 20:22
2501
Antengene Announces XPOVIO® Approved by the TGA in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Triple Class-Refractory Multiple Myeloma
- XPOVIO®, in combination with bortezomib and dexamethasone (XBd), gives patients with relapsed and/or refractory multiple myeloma, a new treatment option. - XPOVIO®, in combination with dexamethasone (Xd), gives patients with triple class refractory multiple myeloma, a new treatment option. ...
2022-03-09 19:08
4056
Adagene Announces Four Poster Presentations on Robust Preclinical Pipeline of Antibody-Based Therapeutics at Upcoming American Association for Cancer Research (AACR) Annual Meeting
* New IND-enabling programs reinforce commitment to build a deep, broad and differentiated pipeline that transforms cancer immunotherapy leveraging company's AI-powered platform - * SAFEbody® precision masking technology integrated across antibody-based modalities in POWERbody® candidates, de...
2022-03-09 10:21
4163
Alphamab Oncology to Present Clinical Data of KN026 Combined with KN046 in HER2-positive Solid Tumors at AACR 2022
SUZHOU, China, March 9, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that data from phase II clinical study (KN026-203) of KN026 (HER2 bispecific antibody) combined with KN046 (PD-L1/CTLA-4 bispecific antibody) will be presented by E- poster at the 113th American Associa...
2022-03-09 09:14
2912
SNIPR BIOME announces opening of new BSL2/GMO2-classified laboratory in Copenhagen, Denmark
COPENHAGEN, Denmark, March 8, 2022 /PRNewswire/ -- SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, is opening a 175 square meter state-of-the-art BSL2/GMO2-classified laboratory inCopenhagen. The new facilities will be among the largest GMO2 laboratories in Scandinavia and...
2022-03-08 15:31
2079
Nippon Express USA Acquires GDP Certification for CFS in Los Angeles and New York
TOKYO, March 8, 2022 /PRNewswire/ -- Nippon Express USA, Inc. (hereinafter "NX USA"), a group company of Nippon Express Holdings, Inc., has obtained Good Distribution Practice (GDP) certification for forwarding operations, inclusive of temporary storage, at temperature-controlled facilities in it...
2022-03-08 14:00
3510
Suvoda Unveils New Brand to Reflect Expanded Focus in Complex Clinical Trial Management
Alongside brand refresh, leading clinical trial technology company announces eConsent and eCOA offerings to better support the patient clinical trial journey. PHILADELPHIA, March 8, 2022 /PRNewswire/ -- Suvoda LLC today launched a refreshed brand, to better reflect its leadership position as a g...
2022-03-08 08:00
2363
HCmed, Formosa Laboratories, and Formosa Pharmaceuticals Signed MoU to Form a Global CDMO for Inhalation Treatment Drugs
TAIPEI, March 7, 2022 /PRNewswire/ -- HCmed Innovations, Co., Ltd. (HCmed) announced that it has formed a strategic alliance with Formosa Laboratories, Inc. (TPEx: 4746) and Formosa Pharmaceuticals, Inc. (TPEx: 6838) to expand its business in the inhalation treatment field, providing contract dev...
2022-03-07 09:00
2832
AnchorDx Appoints Dr. Marina Bibikova as Chief Scientific Officer
GUANGZHOU, China, March 7, 2022 /PRNewswire/ -- AnchorDx, a world-leading developer of cancer screening and early detection solutions, is delighted to announce that Dr. Marina Bibikova has come on board as Chief Scientific Officer (CSO). She will be responsible for cancer early detection technolo...
2022-03-07 09:00
3243
Scientific leaders signal major breakthroughs in elimination of cervical and anal cancers
GENEVA, March 4, 2022 /PRNewswire/ -- To mark International HPV Awareness Day
March 4th 2022, the International Papillomavirus Society (IPVS) has warmly
welcomed two major advances in the elimination of cervical and anal cancers.
2022-03-04 08:01
4458
Sequential Skin debuts Sequential Bio - the world's first in-vivo microbiome testing solution for skin, hair, and personal product industries.
LONDON, NEW YORK and SINGAPORE, March 3, 2022 /PRNewswire/ -- Sequential Skin
Ltd, a leading microbiome company today announced the debut ofSequential Bio
2022-03-03 07:55
3444
Adagene Announces SAFEbody® Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody Candidates
SAN DIEGO and SUZHOU, China, Mar. 2, 2022 /PRNewswire/ -- Adagene Inc. ("Adagene") (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced a collaboration and exclusive license agreement with Sanofi to generate masked monoclonal and bispe...
2022-03-02 19:00
4615
Cambrex Expands Biopharmaceutical Services Business
EAST RUTHERFORD, N.J., March 1, 2022 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced it is significantly expanding its existing b...
2022-03-01 22:00
4002
Ascletis Announces Submission of Marketing Authorization Applications for Ritonavir in Eight Additional European Countries
-- Ritonavir marketing authorization applications have been submitted to Spain, Portugal, Italy, Belgium, Poland, Sweden, the Netherlands and Denmark HANGZHOU, China and SHAOXING, China, March 1, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that it has submitted marketin...
2022-03-01 17:30
4101
Week's Top Stories
Most Reposted
Hong Leong Bank Unveils HLB opus Extended Exclusively by Private Invitation
[Picked up by 317 media titles]
2026-09-03 23:53
Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
[Picked up by 312 media titles]
2026-09-02 12:17
Visa Launches Enhanced A2A Protect Innovations to Help Financial Institutions Stop Fraud Before Money Leaves Accounts
[Picked up by 311 media titles]
2026-09-02 08:30Klook Takes Creator Commerce Beyond Influence With Kreator Shops
[Picked up by 307 media titles]
2026-09-01 11:00
DayOne and TNB Explore Up To 1.5 GW of On-Site Power Generation to Advance Malaysia's Energy Resilience and Digital Economy
[Picked up by 292 media titles]
2026-09-01 17:36Most Read
Klook Takes Creator Commerce Beyond Influence With Kreator Shops
2026-09-01 11:00
6417
YY Group Enters New Era as YYForce, Expanding AI, Automation and Human-Robot Workforce Strategy; Nasdaq Ticker Changes to "YFOR"
2026-09-01 04:10
5997
Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
2026-09-02 12:17
5799
